Document Detail


Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users.
MedLine Citation:
PMID:  23016521     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Anticoagulant treatment with phenprocoumon is challenging because of the narrow therapeutic range and the wide inter- and intra-patient variability in dose response. Frequent monitoring of the international normalized ratio (INR) is therefore required. Polymorphisms in two genes, CYP2C9 and VKORC1 explain approximately one third of the variation in dose requirements [1-3]. © 2012 International Society on Thrombosis and Haemostasis.
Authors:
T I Verhoef; W K Redekop; H Hegazy; A de Boer; A H Maitland-van der Zee;
Publication Detail:
Type:  LETTER     Date:  2012-9-28
Journal Detail:
Title:  Journal of thrombosis and haemostasis : JTH     Volume:  -     ISSN:  1538-7836     ISO Abbreviation:  J. Thromb. Haemost.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101170508     Medline TA:  J Thromb Haemost     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 International Society on Thrombosis and Haemostasis.
Affiliation:
Utrecht Institute of Pharmaceutical Sciences, division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands Erasmus University, Institute for Medical Technology Assessment, Rotterdam Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development and validation of a novel Taqman-based real-time RT-PCR assay suitable for demonstrating...
Next Document:  Enhanced DPPH radical scavenging activity and DNA protection effect of litchi pericarp extract by As...